Technologies
PDF


WARF: P180110US02

  • Patent applied for.

Novel Inhibitors of Pseudomonas aeruginosa Quorum Sensing


INVENTORS -

Helen Blackwell, Daniel Manson

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing the most potent and efficacious compounds found to date that inhibit the P. aeruginosa quorum sensing receptor, LasR.
OVERVIEWThe Gram-negative pathogen Pseudomonas aeruginosa has a high rate of resistance to traditional antibiotics, posing a special risk to cystic fibrosis patients and others with compromised immune systems such as patients undergoing chemotherapy, burn survivors and people with AIDS.

Like other pathogens relevant to human health, P. aeruginosa regulates virulence and biofilm formation via quorum sensing. The quorum sensing receptor LasR is a leading target for antibacterial development, and synthetic molecules capable of modulating receptor-molecule binding events and downstream gene expression are of interest.
THE INVENTIONUW–Madison researchers led by Prof. Helen Blackwell have developed novel inhibitors of LasR, a quorum sensing receptor, in P. aeruginosa. The compounds are analogs of V-06-018, an inhibitor described in the scientific literature in 2006. The potency and efficacy of the compounds – measured by IC50 and maximum inhibition, respectively – were determined to exceed the parent molecule and are the most potent inhibitors of their kind reported to date.
APPLICATIONS
  • Prevention or treatment of P. aeruginosa infection
KEY BENEFITS
  • Potent (3µm IC50 for LasR inhibition)
  • Inhibit QS-related genes and phenotypes
  • Reduced susceptibility to active efflux in P. aeruginosa
  • Hydrolytic stability
  • Could decrease cost of treating bacterial infections involving biofilms, which exceeds $1 billion per year in the U.S.
STAGE OF DEVELOPMENTThe ability of the compounds to inhibit LasR activity was evaluated in a cell-based gene reporter assay.
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.